AcquisitionOther
Reneo Pharmaceuticals, Inc. acquired target
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Reneo Pharmaceuticals, Inc. -> target · $120 million
The combined company will focus on advancing OnKures pipeline candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), including its lead program OKI-219, which is currently in a Phase 1 clinical trial for the treatment of solid tu
Open source record (SEC) ↗